Literature DB >> 7628046

Pharmacokinetics of different doses of methotrexate at steady state by in situ microdialysis in a rat model.

P O Ekstrøm1, A Anderson, D J Warren, K E Giercksky, L Slørdal.   

Abstract

We used a microdialysis technique to monitor extracellular methotrexate (MTX) levels during the steady state in a rodent model. Microdialysis probes were implanted in the muscle, liver, and kidney of anesthetized male Wistar rats. MTX (18.75-500 mg/kg) was given as a continuous infusion through a venous catheter, and blood samples were obtained through a second venous catheter. Heparinized plasma, ultrafiltered plasma, microdialysis effluent from tissues, and tissue samples (obtained at the end of experiments) were analyzed for MTX content by high-performance liquid chromatography (HPLC). Steady state was demonstrated in the blood and tissues from 2 h until the end of the experiments (6 h). Extracellular drug levels in muscle and liver displayed a linear correlation with doses, whereas kidney levels reached a plateau at an MTX dose of 150 mg/kg per 6 h. Microdialysis-fluid endpoint levels for muscle, liver, and kidney were positively correlated to the endpoint total tissue levels (r2 = 0.80, 0.85, and 0.68, respectively). In the kidneys, the maximal relative tissue MTX accumulation was measured at a total dose of 75 mg/kg per 6 h. At higher doses, the relative drug sequestration declined to less than half of the values observed at this dose. This study demonstrates that the microdialysis technique can provide reproducible data on MTX tissue exposure in an animal model and that it offers a means of serial and reproducible monitoring of extracellular-tissue MTX levels at steady state and over a wide dose range. Pending additional studies, microdialysis may be a helpful technique for elucidating the kinetics of drug delivery to both targeted and toxicity-prone tissues during chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7628046     DOI: 10.1007/bf00689044

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Adsorption of methotrexate onto glassware and syringes.

Authors:  M L Chen; W L Chiou
Journal:  J Pharm Sci       Date:  1982-01       Impact factor: 3.534

2.  Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study.

Authors:  G Saeter; T A Alvegård; I Elomaa; A E Stenwig; T Holmström; O P Solheim
Journal:  J Clin Oncol       Date:  1991-10       Impact factor: 44.544

3.  Dose-dependent pharmacokinetics of methotrexate and 7-hydroxymethotrexate in the rat in vivo.

Authors:  R M Bremnes; L Slørdal; E Wist; J Aarbakke
Journal:  Cancer Res       Date:  1989-11-15       Impact factor: 12.701

4.  The protein binding of methotrexate by the serum of normal subjects.

Authors:  W H Steele; J R Lawrence; J F Stuart; C A McNeill
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

5.  Thermal and photolytic decomposition of methotrexate in aqueous solutions.

Authors:  D C Chatterji; J F Gallelli
Journal:  J Pharm Sci       Date:  1978-04       Impact factor: 3.534

6.  The protein binding and elimination of methotrexate after intravenous infusions in cancer patients.

Authors:  J W Paxton
Journal:  Clin Exp Pharmacol Physiol       Date:  1982 May-Jun       Impact factor: 2.557

Review 7.  Microdialysis--principles and applications for studies in animals and man.

Authors:  U Ungerstedt
Journal:  J Intern Med       Date:  1991-10       Impact factor: 8.989

8.  Protein binding of methotrexate in sera from normal human beings: effect of drug concentration, pH, temperature, and storage.

Authors:  J W Paxton
Journal:  J Pharmacol Methods       Date:  1981-05

9.  The protein binding of methotrexate in the serum of patients with neoplastic disease.

Authors:  W H Steele; J R Lawrence; J F Stuart; C A McNeill
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

10.  Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.

Authors:  W E Evans; W R Crom; M Abromowitch; R Dodge; A T Look; W P Bowman; S L George; C H Pui
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

View more
  6 in total

Review 1.  Pharmacokinetic and metabolism studies using microdialysis sampling.

Authors:  D K Hansen; M I Davies; S M Lunte; C E Lunte
Journal:  J Pharm Sci       Date:  1999-01       Impact factor: 3.534

2.  Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models.

Authors:  Xiaoxi Liu; Yuhuan Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-05-23       Impact factor: 2.745

3.  Determination of free extracellular levels of methotrexate by microdialysis in muscle and solid tumor of the rabbit.

Authors:  S Dukic; M L Kaltenbach; B Gourdier; H Marty; R Vistelle
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

4.  Pharmacokinetics of methotrexate in the extracellular fluid of brain C6-glioma after intravenous infusion in rats.

Authors:  S Dukic; T Heurtaux; M L Kaltenbach; G Hoizey; A Lallemand; B Gourdier; R Vistelle
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

5.  Determination of extracellular methotrexate tissue levels by microdialysis in a rat model.

Authors:  P O Ekstrøm; A Andersen; D J Warren; K E Giercksky; L Slørdal
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 6.  Preventing and Managing Toxicities of High-Dose Methotrexate.

Authors:  Scott C Howard; John McCormick; Ching-Hon Pui; Randall K Buddington; R Donald Harvey
Journal:  Oncologist       Date:  2016-08-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.